Luis Colomo

List of Publications by Year
in descending order

44 papers	2,043 citations	471509 17 h-index	377865 34 g-index
45 all docs	45 docs citations	45 times ranked	2726 citing authors

#	Article	IF	Citations
1	Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity. Blood Advances, 2022, 6, 82-86.	5.2	6
2	High PTX3 expression is associated with a poor prognosis in diffuse large Bâ€cell lymphoma. Cancer Science, 2022, 113, 334-348.	3.9	23
3	T cell lymphoblastic lymphoma with uncommon CD20 expression. International Journal of Laboratory Hematology, 2022, 44, 234-235.	1.3	1
4	Dissecting the <scp>sCD3â€CD4</scp>+ Tâ€cell population: A valuable screening tool for angioimmunoblastic Tâ€cell lymphoma. Cytometry Part B - Clinical Cytometry, 2022, 102, 171-174.	1.5	2
5	Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum. Blood Advances, 2022, 6, 3921-3931.	5.2	7
6	Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma. Diagnostics, 2022, 12, 1575.	2.6	6
7	PCM1::JAK2 fusion associates with an atypical form of mycosis fungoides. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 967-973.	2.8	1
8	Evaluation of routine CT scans in the follow-up of diffuse large B-cell lymphomas. Hematology, 2021, 26, 709-715.	1.5	0
9	Diagnostic Value of Genotypic Analysis in Primary Cutaneous Lymphomas using Standardized BIOMED-2 Polymerase Chain Reaction Protocols: Experience in Daily Clinical Practice. Acta Dermato-Venereologica, 2021, 101, adv00460.	1.3	1
10	Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, , 1.	2.8	1
11	Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma With Secondary Cutaneous Involvement: A Diagnostic Challenge. American Journal of Dermatopathology, 2021, 43, 300-304.	0.6	5
12	Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine. Frontiers in Immunology, 2021, 12, 798251.	4.8	1
13	Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features. Blood Advances, 2020, 4, 5285-5296.	5.2	27
14	Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas. Cancers, 2020, 12, 884.	3.7	5
15	Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. Haematologica, 2019, 104, 778-788.	3.5	17
16	Clinical Interest of LMO2 Testing in Aggressive Large B-Cell Lymphomas. Blood, 2019, 134, 2899-2899.	1.4	0
17	Novel phosphorylated TAK1 species with functional impact on NF-Î°B and Î²-catenin signaling in human Cutaneous T-cell lymphoma. Leukemia, 2018, 32, 2211-2223.	7.2	14
18	Essential thrombocythaemia with mutation in MPL: clinicopathological correlation and comparison with JAK2V617F-mutated and CALR-mutated genotypes. Journal of Clinical Pathology, 2018, 71, 975-980.	2.0	12

#	Article	IF	Citations
19	HHV8-related lymphoid proliferations: a broad spectrum of lesions from reactive lymphoid hyperplasia to overt lymphoma. Modern Pathology, 2017, 30, 745-760.	5.5	60
20	LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas. American Journal of Surgical Pathology, 2017, 41, 877-886.	3.7	19
21	Abstract 2169: Pharmacological modulation of CXCL12-CXCR4 intracellular trafficking potentiates thein vitroandin vivoactivity of the BET bromodomain inhibitor CPI203 in diffuse large B-cell lymphoma. , 2017, , .		0
22	In vivo intratumoral Epsteinâ€“Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications. Modern Pathology, 2014, 27, 1599-1611.	5.5	22
23	MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica, 2013, 98, 1554-1562.	3.5	196
24	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood, 2012, 120, 2290-2296.	1.4	53
25	SOX11 is useful in differentiating cyclin D1â€positive diffuse large Bâ€cell lymphoma from mantle cell lymphoma. Histopathology, 2012, 61, 685-693.	2.9	41
26	Nonhepatosplenic Î³Î´ T-cell Lymphomas Represent a Spectrum of Aggressive Cytotoxic T-cell Lymphomas With a Mainly Extranodal Presentation. American Journal of Surgical Pathology, 2011, 35, 1214-1225.	3.7	120
27	Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood, 2011, 117, 4836-4843.	1.4	280
28	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica, 2011, 96, 996-1001.	3.5	100
29	Initial features and outcome of cutaneous and nonâ€cutaneous primary extranodal follicular lymphoma. British Journal of Haematology, 2011, 153, 334-340.	2.5	18
30	IG/MYC Rearrangements are the Main Cytogenetic Alteration in Plasmablastic Lymphomas. American Journal of Surgical Pathology, 2010, 34, 1686-1694.	3.7	251
31	Applicability of Different Immunohistochemistry Algorithms to Assess Gene Expression Profile In Patients with Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 4134-4134.	1.4	0
32	T-Cell Subpopulations Quantified by Flow Cytometry in Lymph Node Cell Suspensions Identify a Group of Patients with Follicular Lymphoma with Good Prognosis.. Blood, 2009, 114, 1945-1945.	1.4	0
33	High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT).. Blood, 2009, 114, 1948-1948.	1.4	0
34	Primary neuroendocrine small cell undifferentiated carcinoma of the parotid gland. Clinical and Translational Oncology, 2008, 10, 303-306.	2.4	13
35	Diagnostic efficacy of bone scintigraphy, magnetic resonance imaging, and positron emission tomography in bone metastases of myxoid liposarcoma. Journal of Magnetic Resonance Imaging, 2008, 27, 625-628.	3.4	22
36	Diagnosis of pleural malignant mesothelioma by EUS-guided FNA (with video). Gastrointestinal Endoscopy, 2008, 68, 1191-1193.	1.0	7

#	Article	IF	Citations
37	Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Annals of Oncology, 2008, 19, 958-963.	1.2	182
38	Primary Cutaneous Small/Medium CD4⁺ T-Cell Lymphomas: A Heterogeneous Group of Tumors With Different Clinicopathologic Features and Outcome. Journal of Clinical Oncology, 2008, 26, 3364-3371.	1.6	163
39	No Benefit from Rituximab Containing Regimens in Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma. Blood, 2008, 112, 3615-3615.	1.4	5
40	Epstein-Barr Virus Negative Clonal Plasma Cell Proliferations and Lymphomas in Peripheral T-cell Lymphomas. American Journal of Surgical Pathology, 2007, 31, 1310-1322.	3.7	77
41	Lack of Methylthioadenosine Phosphorylase Expression in Mantle Cell Lymphoma Is Associated with Shorter Survival: Implications for a Potential Targeted Therapy. Clinical Cancer Research, 2006, 12, 3754-3761.	7.0	31
42	Activation of the Endoplasmic Reticulum (ER) Unfolded Protein Response (UPR) in Aggressive B-Cell Lymphomas.. Blood, 2006, 108, 2038-2038.	1.4	0
43	Primary Extranodal Follicular Lymphoma: Clinicobiological Features and Outcome.. Blood, 2006, 108, 2456-2456.	1.4	0
44	Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin. Journal of Clinical Oncology, 2005, 23, 2797-2804.	1.6	253